Clinical Trials Results - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -8 of 8 Show results per page	View Search Criteria \| Help With Results

Last Modified: 10/18/2006 First Published: 11/1/2001


1.		Phase II/III Randomized Study of Exisulind as Chemoprevention of Duodenal Polyps in Patients With Familial Adenomatous Polyposis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Prevention				Closed				18 to 80				Other				UUMC-IRB-5999-96 NCI-H01-0079, NCT00026468

Last Modified: 1/17/2006 First Published: 7/1/2001


2.		Phase III Randomized Study of Docetaxel With or Without Exisulind in Patients With Advanced Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				CPI-028


3.		Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				Pharmaceutical / Industry				026B NCT00072618

Last Modified: 12/1/1998 First Published: 7/1/1998


4.		Phase II Randomized Study of Sulindac Sulfone (FGN-1) for Preventing the Recurrence of Prostate Cancer (Summary Last Modified 12/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention, Treatment				Closed				18 and over				Pharmaceutical / Industry				UCLA-HSPC-971104401 CELLPATH-012, NCI-V98-1405

Last Modified: 8/15/2007 First Published: 7/1/2002


5.		Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients With Extensive Stage Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				CLB-30104 NCT00041054, CALGB-30104

Last Modified: 2/8/2007 First Published: 7/1/2002


6.		Phase II Study of Carboplatin, Gemcitabine, and Exisulind in Patients With Advanced Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				E-E1501 NCT00041314

Last Modified: 10/7/2008 First Published: 11/24/2002


7.		Phase II Study of Docetaxel, Estramustine, and Exisulind in Patients With Hormone- Refractory Metastatic Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				CALGB-90004 NCT00052845

Last Modified: 4/13/2007 First Published: 2/20/2004


8.		Phase II Study of Neoadjuvant Exisulind in Patients With Stage II or III Prostate Cancer Undergoing Radical Prostatectomy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				40 and over				NCI				MAYO-229701 NCT00078910

Select All on One Page